Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were eligible for inclusion.
Specific interventions included in the review
Studies that had administered non-white blood cell (WBC)-reduced allogeneic red blood cells (RBCs) or whole blood to the treatment arm, and either WBC-reduced allogeneic RBCs (or whole blood) and/or autologous blood obtained by pre-operative autologous blood donation, acute normovolemic haemodilation, intra-operative blood recovery and/or post-operative blood recovery, were eligible for inclusion.
Participants included in the review
No inclusion criteria were specified in relation to the participants. The participants came from a number of clinical settings, including patients for open-heart surgery, colorectal surgery, aortic aneurysm repair, resection of gastrointestinal malignancies, burn trauma surgery, HIV-seropositive and general hospitalised patients.
Outcomes assessed in the review
Studies that had assessed an adverse immunomodulatory effect of ABT (including cancer recurrence, post-operative infection, mortality or virus activation), and had reported the odds ratio (OR) of mortality from all causes in the treatment versus the control arm, were included.
How were decisions on the relevance of primary studies made?
The author did not state how the papers were selected for the review, or how many reviewers performed the assessment.